BI 1467335

Drug Profile

BI 1467335

Alternative Names: PXS 4728A

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmaxis
  • Developer Boehringer Ingelheim; Pharmaxis; University of Sydney
  • Class Anti-inflammatories; Hepatoprotectants; Recombinant fusion proteins; Small molecules
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic retinopathy; Non-alcoholic steatohepatitis
  • Phase I Chronic obstructive pulmonary disease; Cystic fibrosis
  • Preclinical Asthma; Renal fibrosis

Most Recent Events

  • 17 Oct 2017 Boehringer Ingelheim initiates enrolment in a phase I trial in healthy volunteers and patients with moderate renal impairment in Germany (NCT03302091)
  • 09 Oct 2017 Boehringer Ingelheim plans a phase I trial in Healthy volunteers(NCT03302091)
  • 19 Sep 2017 Phase-II clinical trials in Diabetic retinopathy in USA (PO) (NCT03238963)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top